Subscribe To
Pipeline moves: approval prospects rise for oesophageal cancer drug after trial completion
On a good note, we investigate the completion of a Phase IIb trial in congestive heart failure and chronic kidney disease, a Phase II trial in triple-...
November 2, 2023, 8:29 pm
Lisata therapeutics announces first patient treated in the cholangiocarcinoma cohort of the bolster trial of lsta1, a novel tumor-targeting and penetrating peptide
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-car...
October 24, 2023, 12:00 pm
Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...
October 22, 2023, 6:59 pm
: merck’s keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing che...
October 20, 2023, 12:13 pm
Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...
October 20, 2023, 8:13 am
Alx oncology: on right track with latest interim analysis of evorpacept
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastro...
October 9, 2023, 12:38 am
Alx oncology stock doubles on early data from phase ii cancer trial
ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing th...
October 3, 2023, 8:47 am
Fda accepts sanofi's (sny) sbla for dupixent in pediatric eoe
If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic ...
September 26, 2023, 9:46 am
Dupixent® (dupilumab) sbla for treatment of eosinophilic esophagitis (eoe) in children aged 1 to 11 accepted for fda priority review
If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 infla...
September 26, 2023, 5:29 am
Voyageur pharmaceuticals achieves milestone in the development of hdxba barium contrast media
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) told investors it has completed the formulation and engineering for production processing of its dr...
September 14, 2023, 9:43 am
An old dog with a new trick… ellodi’s apt-1011 promises eoe patients a convenient and potent treatment alternative
Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE treatment gold standard, Dupixe...
August 15, 2023, 7:40 pm
Harvard apparatus regenerative technology schedules conference call and webcast for q2 2023 results
HOLLISTON, Mass. , Aug. 9, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("HRGN" or the "Company"), a clinical-s...
August 9, 2023, 2:54 pm
Prophase labs continues to make the right moves - reiterate strong buy
ProPhase Labs thrived in the Covid era and then wisely used the gains to invest in new testing capabilities including whole genome sequencing and a ne...
June 11, 2023, 1:16 am
Leap therapeutics to present updated data from part a of the distinguish study of dkn-01 plus tislelizumab and chemotherapy in gastric cancer patients at the 2023 asco annual meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient wit...
May 25, 2023, 5:10 pm
Revolo biotherapeutics announces positive topline data from phase 2a trial of ‘1104 in adults with active eosinophilic esophagitis
– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil coun...
April 19, 2023, 12:00 pm
Merck's (mrk) keytruda sbla accepted by fda for gastric cancer
Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treat...
April 14, 2023, 3:12 pm
Pharmadrug unveils plans for first-in-human clinical study with its lead drug candidate pd-001 in esophageal cancer
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) revealed that it intends to pursue a first-in-human study of its lead drug candidate cepharanthine-2HCL (PD-001...
February 13, 2023, 9:11 am
Phathom's stock falls after receiving fda letters
Shares of Phathom Pharmaceuticals Inc. PHAT, -0.60% tumbled about 23% in premarket trading on Friday, the day after the company said it received compl...
February 10, 2023, 7:59 am
Newly established stockbridge police department implements industry-leading esoph background software
STOCKBRIDGE, Ga., Jan. 30, 2023 (GLOBE NEWSWIRE) — The Stockbridge Police Department recently completed the implementation of Miller Mendel, Inc.’...
January 30, 2023, 7:11 pm
Dupixent® (dupilumab) approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remiss...
January 30, 2023, 6:00 am
